Danone Recalls Infant Formula Due to Cereulide Contamination from Chinese ARA Oil

Dublin, Ireland — 23 January 2026

Danone has initiated a recall for specific batches of infant and follow-on formula due to the potential presence of cereulide, a toxin produced by Bacillus cereus. While no affected products were distributed within Ireland, the implicated batches, manufactured in Ireland, were exported to multiple markets including the EU, UK, and other third countries. The Food Safety Authority of Ireland (FSAI) facilitated coordinated alerts through the Rapid Alert System for Food and Feed (RASFF) to ensure international notification.

This recall stems from a contaminated raw ingredient: ARA (arachidonic acid) oil. The oil, manufactured in China, was found to contain cereulide and was subsequently incorporated into base powders used for formula production. This incident mirrors a recent recall by Nestlé involving similar products and the same contaminated ARA oil component, highlighting a broader supply chain issue for speciality lipids critical to infant nutrition formulations.

The recurring nature of this contamination, originating from a single ingredient source, underscores a significant risk in the global procurement of sensitive raw materials. Manufacturers leveraging complex international supply chains for nutritional ingredients, particularly those from Asian markets, must reassess their quality control checkpoints and supplier validation processes. The FSAI and the Department of Agriculture, Food and the Marine are actively engaging with Danone's Irish manufacturing facilities to ensure comprehensive food safety measures are in place following this incident.

What this means for United Kingdom

UK brand owners importing infant or follow-on formulae, or sourcing ingredients from the identified supply chain, should immediately review Certificate of Analysis (CoA) documentation for all ARA oil and related lipid components. Reformulation windows for affected products or the implementation of urgent, enhanced in-house batch testing for cereulide will be critical to maintaining market access and consumer trust. Compliance with FSA (Food Standards Agency) and MHRA (Medicines and Healthcare products Regulatory Agency) guidelines for infant nutrition will be under increased scrutiny, potentially leading to increased regulatory sampling. Proactive communication with trade partners and consumers will be essential to mitigate brand damage and maintain market share against competitors not impacted by this specific supply chain failure.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.